Bolt Biotherapeutics, Inc. Common Stock (BOLT) Stock Price

BOLTStock

$4.00−31.77%52W

Market Cap$7.71M

P/E—

PEG Ratio—

Div yield—

Beta0.96

BOLT Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-25.52%

Price vs S&P 500 (4W)12.75%

VGM Score53.10

Book Value / Share (Quarterly)$6.56

P/TBV (Annual)0.20x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)10.33%

Cash Flow / Share (Quarterly)$-16.37

Price vs S&P 500 (YTD)-38.77%

Net Profit Margin (TTM)-611.47%

EPS (TTM)$-16.44

10-Day Avg Trading Volume0.03M

EPS Excl Extra (TTM)$-16.44

Revenue Growth (5Y)101.79%

EPS (Annual)$-17.85

ROI (Annual)-125.92%

Net Profit Margin (5Y Avg)-2299.04%

Cash / Share (Quarterly)$9.14

Revenue Growth QoQ (YoY)-99.72%

ROA (Last FY)-58.81%

Revenue Growth TTM (YoY)12.79%

EBITD / Share (TTM)$-17.01

ROE (5Y Avg)-77.69%

Operating Margin (TTM)-654.53%

Cash Flow / Share (Annual)$-20.79

P/B Ratio0.61x

P/B Ratio (Quarterly)0.59x

Net Income / Employee (Annual)$-1,451,100

EV / Revenue (TTM)-1.10x

ROA (TTM)-54.70%

EPS Incl Extra (Annual)$-17.85

Current Ratio (Annual)3.59x

Quick Ratio (Quarterly)2.26x

3-Month Avg Trading Volume0.03M

52-Week Price Return-31.77%

Revenue / Employee (TTM)$204,300

Tangible BV / Share (Quarterly)$3.38

P/S Ratio (Annual)1.00x

Asset Turnover (Annual)0.14x

52-Week High$7.20

Operating Margin (5Y Avg)-2253.29%

EPS Excl Extra (Annual)$-17.85

CapEx CAGR (5Y)-53.35%

26-Week Price Return-15.61%

Quick Ratio (Annual)3.40x

13-Week Price Return-9.50%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)2.61x

Enterprise Value$-5.15M

Revenue / Share Growth (5Y)265.60%

Asset Turnover (TTM)0.09x

Revenue / Employee (Annual)$334,600

Pretax Margin (Annual)-433.74%

Cash / Share (Annual)$14.32

3-Month Return Std Dev76.46%

Net Income / Employee (TTM)$-1,249,500

ROE (Last FY)-125.92%

EPS Basic Excl Extra (Annual)$-17.85

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-16.44

ROI (TTM)-126.23%

P/S Ratio (TTM)1.64x

Pretax Margin (5Y Avg)-2299.04%

Revenue / Share (Annual)$4.12

Tangible BV / Share (Annual)$4.54

Price vs S&P 500 (52W)-47.31%

Year-to-Date Return-26.85%

5-Day Price Return-5.66%

EPS Normalized (Annual)$-17.85

ROA (5Y Avg)-47.24%

Net Profit Margin (Annual)-433.74%

Month-to-Date Return8.70%

Cash Flow / Share (TTM)$-1.84

EBITD / Share (Annual)$-18.62

Operating Margin (Annual)-469.30%

ROI (5Y Avg)-77.69%

EPS Basic Excl Extra (TTM)$-16.44

P/TBV (Quarterly)0.27x

P/B Ratio (Annual)0.40x

Pretax Margin (TTM)-611.47%

Book Value / Share (Annual)$13.80

Price vs S&P 500 (13W)-12.19%

Beta0.96x

Revenue / Share (TTM)$2.78

ROE (TTM)-126.23%

52-Week Low$3.10

gGradeC

mGradeC

vgmGradeC

BOLT Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 11, 2026	-$21.06	-$4.57	+78.30%(+$16.49)
Q4 2025	Mar 12, 2026	-$5.52	-$2.98	+45.95%(+$2.54)
Q3 2025	Nov 12, 2025	-$5.39	-$3.72	+31.05%(+$1.67)
Q2 2025	Aug 14, 2025	-$6.27	-$4.46	+28.83%(+$1.81)

BOLT Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

3.90

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
BOLTBolt Biotherapeutics, Inc. Common Stock	—	C	C	1.6x	12.8%	—	—	$4.00
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Bolt Biotherapeutics, Inc. Common Stock

Bolt Biotherapeutics is a clinical-stage immuno-oncology company developing tumor-targeted therapies that activate both innate and adaptive immune responses. The company's proprietary Boltbody ISAC platform combines tumor-targeting antibodies with immune-stimulating payloads, leveraging deep expertise in myeloid biology. Its pipeline includes three candidates: BDC-1001, BDC-3042, and a next-generation ISAC therapeutic.

BOLT Insider Transactions

SellSep 18, 2026
QUINN WILLIAM P
Chief Executive Officer
Shares: 17,566Value: $58,402
SellSep 18, 2026
YONEHIRO GRANT
Chief Operating Officer
Shares: 13,176Value: $43,807
SellSep 18, 2026
NEMEC SARAH
Officer
Shares: 7,842Value: $26,072

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

BONBon Natural Life Limited Class A Ordinary SharesPharmaceutical Preparations
TANHTantech Holdings Ltd. Class A Common SharesIndustrial Chemicals
BMRABIOMERICA INCIn Vitro Diagnostics
FRTTFort Technology Inc. Common SharesAgricultural Chemicals
NAIINatural Alternatives International Inc.Pharmaceutical Preparations
SNTISenti Biosciences Holdings, Inc. Common StockBiological Products
AIMAIM ImmunoTech Inc.Biological Products
BIOTInstinct Bio Technical Company Holdings Inc. Ordinary SharesCosmetics & Toiletries

Same SIC sector, outside this company's own industry.

Analyst Sentiment

3.9

Buy

Consensus rating

52-Week Range

Low$3.10

High$7.20